Br[C:2]1[C:10]2[N:9]=[CH:8][N:7]([C:11]([C:18]3[CH:23]=[CH:22][CH:21]=[CH:20][CH:19]=3)=[CH:12][C:13]([O:15][CH2:16][CH3:17])=[O:14])[C:6]=2[CH:5]=[C:4]([C:24]([F:27])([F:26])[F:25])[CH:3]=1.C([O-])=O.[NH4+]>C(O)C.[Pd]>[C:18]1([CH:11]([N:7]2[C:6]3[CH:5]=[C:4]([C:24]([F:26])([F:27])[F:25])[CH:3]=[CH:2][C:10]=3[N:9]=[CH:8]2)[CH2:12][C:13]([O:15][CH2:16][CH3:17])=[O:14])[CH:23]=[CH:22][CH:21]=[CH:20][CH:19]=1To a solution of ethyl 3-[4-bromo-6-(trifluoromethyl)-1H-benzimidazol-1-yl]-3-phenyl-2-propenoate (111 mg, 253 μmol) in ethanol (4 mL) was added palladium on carbon (23 mg, 10% w/w Pd) and ammonium formate (159 mg, 2.52 mmol). The suspension was heated to reflux for 3 hours, then cooled to room temperature, and filtered through a pad of Celite®. The filtrate was evaporated in vacuo to afford the title compound, 1H NMR: (CDCl3), 8.10 (s, 1H), 7.79 (d, J=8.79, 1H), 7.49 (s, 1H), 7.42 (d, H=8.79, 1H), 7.31-7.23 (m, 3H), 7.18-7.14 (m, 2H), 6.00 (dd, J=6.96, 6.96, 1H), 3.98 (q, J=7.32, 2H), 3.36-3.25 (m, 2H), 1.03 (t, J=7.32, 3H).